NCPA, Purdue Pharma release pharmacy crime video
STAMFORD, Conn. — Drug maker Purdue Pharma and the National Community Pharmacists Association have introduced the latest version of a video designed to educate pharmacists and other pharmacy staff about pharmacy crime.
The video, part of RxPatrol, Purdue’s broader initiative to combat pharmacy crime, launched on the initiative’s website. Titled "RxPatrol Pharmacy Safety and Security," it is free of charge, and is part of the NCPA’s Protect Your Pharmacy Now! initiative, which started in 2008.
The video features NCPA member Tony Sumpter and retired assistant special agent in charge of the Virginia State Police Landon Gibbs discussing ways to prevent and deal with internal theft and prescription fraud; touring Sumpter’s store, a Medicap Pharmacy in Adel, Iowa; and evaluating security measures and discussing additional steps to take to prevent internal theft and fraud.
"Pharmacy crime affects our customers, our staff and our businesses," NCPA president Donnie Calhoun said. "As communities across the country experience internal theft and prescription fraud, NCPA is pleased to continue our Protect Our Pharmacy Now! partnership with Purdue’s RxPatrol program to help our members prevent pharmacy crime."
Reports: CVS Caremark drops 17 drugs from formulary
NEW YORK — The PBM division of CVS Caremark is hoping to get patients to use lower-cost drugs for certain conditions by removing higher-cost drugs from its formulary, according to published reports.
The Wall Street Journal reported that CVS Caremark would stop covering 17 drugs starting on Jan. 1, 2013, after removing 30 this year. The drugs include Abbott’s Androgel (testosterone gel) for low testosterone, and Pfizer’s drug Detrol LA (tolterodine tartrate) for overactive bladder.
The company said that the drugs removed from the formulary have alternatives that cost less, including generics, and some of those removed were nonpreferred drugs with lower degrees of utilization, according to the WSJ, adding that the removals are considered voluntary, but clients using the PBM’s services risk getting a smaller share of rebates if they don’t follow the policy.
FDA approves new strength of HIV drug
TITUSVILLE, N.J. — The Food and Drug Administration has approved a new strength of a drug for HIV made by Johnson & Johnson, the drug maker said.
J&J subsidiary Janssen Therapeutics announced the approval of an 800-mg formulation of Prezista (darunavir) as a once-daily treatment for HIV. The drug is designed to be taken with food at the same time as ritonavir and in combination with other HIV drugs.
"The single 800-mg tablet provides an option for a reduced pill burden and reflects our ongoing commitment to offer more treatment options for the diverse population of people living with HIV," Janssen Therapeutics medical director Bryan Baugh said.